Ventyx Biosciences to be Sold to Eli Lilly for $14 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: PRnewswire
- Transaction Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm are investigating the proposed sale of Ventyx Biosciences to Eli Lilly for $14 per share, aiming to assess whether this consideration undervalues the company.
- Shareholder Rights Concern: Kahn Swick & Foti is seeking to confirm the adequacy of the transaction process, ensuring that Ventyx shareholders receive fair compensation that reflects the company's future potential.
- Legal Consultation Services: KSF offers no-obligation legal consultations, encouraging shareholders to discuss the potential undervaluation of the deal, demonstrating a commitment to protecting investor rights.
- Market Reaction Anticipation: This investigation may impact shareholder confidence in Ventyx, potentially exerting short-term pressure on its stock price, reflecting the market's heightened concern over the fairness of the transaction.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1087.380
Low
950.00
Averages
1192
High
1500
Current: 1087.380
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
